2016
DOI: 10.4172/pharmaceutical-sciences.1000172
|View full text |Cite
|
Sign up to set email alerts
|

Teixobactin: A Powerful Tool for Combating Resistant Strains

Abstract: Resistance to antibiotics has grown out to be a serious health concern. Despite this serious health crisis, no new antibiotics have been discovered since the last 30 years. A new ray of hope in the form of teixobactin has come out of the dark, which could demonstrate the potential to be effective in countering resistance. This new antibiotic has an interesting mechanism of action against bacteria. The discovery of this wonderful compound has evolved as a major breakthrough especially in this era of antibiotic … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 10 publications
0
1
0
Order By: Relevance
“…Teixobactin exhibits potent antibacterial activity against all the tested gram-positive pathogens and Mycobacterium tuberculosis, including drug-resistant strains. 22,29 Compared with the wellestablished lipid II inhibitor vancomycin, teixobactin binds to both bacterial lipid II and lipid III that are precursor molecules in the synthesis of bacterial cell wall, which demonstrates the superiority of teixobactin in bacterial resistance. Strikingly, the in vivo antibactericidal activity of teixobactin is 10-fold superior than the last-line clinical drug vancomycin in mouse models.…”
mentioning
confidence: 99%
“…Teixobactin exhibits potent antibacterial activity against all the tested gram-positive pathogens and Mycobacterium tuberculosis, including drug-resistant strains. 22,29 Compared with the wellestablished lipid II inhibitor vancomycin, teixobactin binds to both bacterial lipid II and lipid III that are precursor molecules in the synthesis of bacterial cell wall, which demonstrates the superiority of teixobactin in bacterial resistance. Strikingly, the in vivo antibactericidal activity of teixobactin is 10-fold superior than the last-line clinical drug vancomycin in mouse models.…”
mentioning
confidence: 99%